SCHEMBL4917286

SCHEMBL4917286

COc1ccc(CNC(=O)c2cc3ccccc3o2)c(OC)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 6/20 0.67
L3MBTL1 Q9Y468 2/20 0.67
TSHR P16473 3/20 0.64
ALDH1A1 P00352 3/20 0.64
HPGD P15428 3/20 0.64
NPSR1 Q6W5P4 2/20 0.64
HSD17B10 Q99714 2/20 0.64
KDM4E B2RXH2 1/20 0.64
SMN1; SMN2 Q16637 4/20 0.62
HTT P42858 3/20 0.62
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
MAPK1 P28482 1/20 0.62
NPC1 O15118 2/20 0.59
RAB9A P51151 2/20 0.59
MAPT P10636 1/20 0.59
NAMPT P43490 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
TAS1R3 Q7RTX0 1/20 0.56
TAS1R1 Q7RTX1 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4925243 0.86 SMN1; SMN2 (0.54) TP53L3MBTL1TSHRALDH1A1HPGD
SCHEMBL4925047 0.82 TP53 (0.61) TP53L3MBTL1TSHRALDH1A1HPGD
SCHEMBL9852060 0.79 ACHE (0.60) TP53TSHRALDH1A1HPGDNPSR1
SCHEMBL8759043 0.78 HPGD (0.70) TP53TSHRALDH1A1HPGDNPSR1
SCHEMBL4924298 0.78 GPR55 (0.78) L3MBTL1TSHRALDH1A1HPGDNPSR1
SCHEMBL4929553 0.77 KMT2A (0.55) TP53TSHRALDH1A1HPGDNPSR1
SCHEMBL19326905 0.76 HPGD (0.74) TP53TSHRALDH1A1HPGDNPSR1
SCHEMBL4927411 0.75 MEN1 (0.77) TP53TSHRALDH1A1HPGDNPSR1
SCHEMBL6661736 0.75 KDM4E (0.64) ALDH1A1HPGDKDM4EHTTMEN1
SCHEMBL4926069 0.75 CLK1 (0.64) TP53TSHRALDH1A1HPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity DEVGEN NV (BE) 2008-02-14 US claimed
EP-1838690-A2 COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY Devgen N.V. (BE) 2007-10-03 EP claimed
WO-2006066879-A2 COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY DEVGEN N.V. (BE) 2006-06-29 WO claimed
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity DEVGEN NV (BE) 2008-02-14 US disclosed
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity DEVGEN NV (BE) 2008-02-14 US disclosed
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity DEVGEN NV (BE) 2008-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity KCNA4, HCN4, KCNN4 TP53 4191/4885L3MBTL1 1222/4885TSHR 1950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.